Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects-Reference-Cited by-同舟云学术

Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects

Published:2024-07-12 Issue:8 Volume:33 Page:867-876
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Liu Jian¹^ORCID,Zhao Qingwei¹,Zhai You¹,Wu Xia¹,Kai Jiejing¹,Ruan Jie¹,Wu Minglan¹,Wu Meijia¹,Zhou Zhuojun¹,Yan Yuemei²,Wu Jinzi J.²,Qiu Yunqing³

Affiliation:

1. Research Center for Clinical Pharmacy, Department of Clinical Pharmacy, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

2. Department of Clinical Research, Ascletis BioScience Co, Ltd, Hangzhou, Zhejiang, China

3. Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Funder

Ascletis BioScience

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2024.2377318

Reference12 articles.

1. WHO COVID-19 dashboard [Internet]. 2024 [cited 2024 Jun 6]. Available from: https://covid19.who.int/

2. The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape

3. COVID-19 vaccine breakthrough infections

4. Omicron: Call for updated vaccines

5. Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies